• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TRIM33是雌激素受体α的协同调节因子。

TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha.

作者信息

Romo Bianca A, Karakyriakou Barbara, Cressey Lauren, Brauer Brooke L, Yang Huijuan, Warren Alexa, Johnson Anneka L, Kettenbach Arminja N, Miller Todd W

机构信息

Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA.

Department of Biochemistry and Cell Biology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03755, USA.

出版信息

Cancers (Basel). 2024 Feb 20;16(5):845. doi: 10.3390/cancers16050845.

DOI:10.3390/cancers16050845
PMID:38473207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10930732/
Abstract

Estrogen receptor alpha (ER)-positive breast cancer is responsible for over 60% of breast cancer cases in the U.S. Among patients diagnosed with early-stage ER+ disease, 1/3 will experience recurrence despite treatment with adjuvant endocrine therapy. ER is a nuclear hormone receptor responsible for estrogen-driven tumor growth. ER transcriptional activity is modulated by interactions with coregulators. Dysregulation of the levels of these coregulators is involved in the development of endocrine resistance. To identify ER interactors that modulate transcriptional activity in breast cancer, we utilized biotin ligase proximity profiling of ER interactomes. Mass spectrometry analysis revealed tripartite motif containing 33 (TRIM33) as an estrogen-dependent interactor of ER. shRNA knockdown showed that TRIM33 promoted ER transcriptional activity and estrogen-induced cell growth. Despite its known role as an E3 ubiquitin ligase, TRIM33 increased the stability of endogenous ER in breast cancer cells. TRIM33 offers a novel target for inhibiting estrogen-induced cancer cell growth, particularly in cases of endocrine resistance driven by ER () gene amplification or overexpression.

摘要

雌激素受体α(ER)阳性乳腺癌占美国乳腺癌病例的60%以上。在被诊断为早期ER+疾病的患者中,尽管接受了辅助内分泌治疗,仍有三分之一的患者会复发。ER是一种核激素受体,负责雌激素驱动的肿瘤生长。ER的转录活性通过与共调节因子的相互作用来调节。这些共调节因子水平的失调与内分泌抵抗的发生有关。为了鉴定调节乳腺癌中转录活性的ER相互作用蛋白,我们利用了ER相互作用组的生物素连接酶邻近分析。质谱分析显示,含三联基序蛋白33(TRIM33)是ER的雌激素依赖性相互作用蛋白。短发夹RNA(shRNA)敲低表明,TRIM33促进了ER的转录活性和雌激素诱导的细胞生长。尽管TRIM33已知具有E3泛素连接酶的作用,但它增加了乳腺癌细胞中内源性ER的稳定性。TRIM33为抑制雌激素诱导的癌细胞生长提供了一个新靶点,特别是在由ER()基因扩增或过表达驱动的内分泌抵抗病例中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/d632023c63e1/cancers-16-00845-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/fd04f3c24a09/cancers-16-00845-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/321638b0eca4/cancers-16-00845-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/bde22930cd4e/cancers-16-00845-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/3b46c41d769e/cancers-16-00845-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/d632023c63e1/cancers-16-00845-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/fd04f3c24a09/cancers-16-00845-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/321638b0eca4/cancers-16-00845-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/bde22930cd4e/cancers-16-00845-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/3b46c41d769e/cancers-16-00845-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/185b/10930732/d632023c63e1/cancers-16-00845-g005.jpg

相似文献

1
TRIM33 Is a Co-Regulator of Estrogen Receptor Alpha.TRIM33是雌激素受体α的协同调节因子。
Cancers (Basel). 2024 Feb 20;16(5):845. doi: 10.3390/cancers16050845.
2
Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.雌激素受体α转录共调节因子在乳腺癌他莫昔芬耐药中的作用
Maturitas. 2006 Jul 20;54(4):342-51. doi: 10.1016/j.maturitas.2006.06.003. Epub 2006 Jul 5.
3
Knockdown of ZBTB7A inhibits cell proliferation of breast cancer through regulating the ubiquitination of estrogen receptor alpha.敲低 ZBTB7A 通过调控雌激素受体α的泛素化抑制乳腺癌细胞增殖。
Life Sci. 2019 Dec 15;239:117042. doi: 10.1016/j.lfs.2019.117042. Epub 2019 Nov 9.
4
The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).晚期乳腺癌中雌激素受体-1突变的患病率:雌激素受体一项研究(EROS1)
Cancer Treat Res Commun. 2019;19:100123. doi: 10.1016/j.ctarc.2019.100123. Epub 2019 Feb 21.
5
WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.WNT4介导浸润性小叶癌细胞系中的雌激素受体信号传导和内分泌抗性。
Breast Cancer Res. 2016 Sep 20;18(1):92. doi: 10.1186/s13058-016-0748-7.
6
TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression.TRIM3 促进雌激素信号转导并调节乳腺癌细胞的进展。
Cell Commun Signal. 2022 Apr 7;20(1):45. doi: 10.1186/s12964-022-00861-z.
7
The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer.E3 连接酶 TRIM4 促进 SET 泛素化介导的降解,增强乳腺癌中 ER-α 的作用。
Adv Sci (Weinh). 2022 Sep;9(25):e2201701. doi: 10.1002/advs.202201701. Epub 2022 Jul 17.
8
SMURF1 facilitates estrogen receptor ɑ signaling in breast cancer cells.SMURF1 促进乳腺癌细胞中雌激素受体 α 的信号转导。
J Exp Clin Cancer Res. 2018 Feb 12;37(1):24. doi: 10.1186/s13046-018-0672-z.
9
Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.雌激素治疗诱导未折叠蛋白反应以驱动 ER+ 乳腺癌细胞死亡。
Mol Oncol. 2019 Aug;13(8):1778-1794. doi: 10.1002/1878-0261.12528. Epub 2019 Jul 9.
10
Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating Mutation.孕激素受体的纵向分子成像揭示了携带激活突变的乳腺癌对内分泌治疗的早期差异反应。
J Nucl Med. 2021 Apr;62(4):500-506. doi: 10.2967/jnumed.120.249508. Epub 2020 Aug 28.

本文引用的文献

1
Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer.雌激素治疗诱导 ER+ 乳腺癌中 PARP 抑制增强的受体依赖性 DNA 损伤。
Clin Cancer Res. 2023 Sep 15;29(18):3717-3728. doi: 10.1158/1078-0432.CCR-23-0488.
2
Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer.发现和评估浆液性卵巢癌中最稳健的预后生物标志物。
Geroscience. 2023 Jun;45(3):1889-1898. doi: 10.1007/s11357-023-00742-4. Epub 2023 Mar 1.
3
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
4
TRIM proteins in breast cancer: Function and mechanism.乳腺癌中的TRIM蛋白:功能与机制
Biochem Biophys Res Commun. 2023 Jan 15;640:26-31. doi: 10.1016/j.bbrc.2022.11.103. Epub 2022 Dec 5.
5
TurboID functions as an efficient biotin ligase for BioID applications in Xenopus embryos.TurboID 作为一种高效的生物素连接酶,可用于爪蟾胚胎的 BioID 应用。
Dev Biol. 2022 Dec;492:133-138. doi: 10.1016/j.ydbio.2022.10.005. Epub 2022 Oct 18.
6
Proximity labeling of endogenous RICTOR identifies mTOR complex 2 regulation by ADP ribosylation factor ARF1.内源性 RICTOR 的临近标记鉴定了由 ADP 核糖基化因子 ARF1 调节的 mTOR 复合物 2。
J Biol Chem. 2022 Oct;298(10):102379. doi: 10.1016/j.jbc.2022.102379. Epub 2022 Aug 13.
7
TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.TRIM33 通过稳定 Skp2 介导的雄激素受体降解来驱动前列腺肿瘤生长。
EMBO Rep. 2022 Aug 3;23(8):e53468. doi: 10.15252/embr.202153468. Epub 2022 Jul 4.
8
Comprehensive Interactome Mapping of Nuclear Receptors Using Proximity Biotinylation.利用邻近生物素化技术对核受体进行全面的相互作用组图谱绘制。
Methods Mol Biol. 2022;2456:223-240. doi: 10.1007/978-1-0716-2124-0_15.
9
Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast.DNA 损伤检查点 1(MDC1)介体是乳腺浸润性小叶癌中的一种新型雌激素受体共调节子。
Mol Cancer Res. 2021 Aug;19(8):1270-1282. doi: 10.1158/1541-7786.MCR-21-0025. Epub 2021 May 4.
10
High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer.高雌激素受体α的激活赋予了对雌激素剥夺的抗性,并对乳腺癌对雌激素的治疗反应是必需的。
Oncogene. 2021 May;40(19):3408-3421. doi: 10.1038/s41388-021-01782-w. Epub 2021 Apr 19.